Whether cardiac troponin concentrations are increased by reversible myocardial ischemia is controversial. Differences in the structure of cardiac troponin I (cTnI) and cTnT may have implications for diagnostic utility.
cardiovascular disease, the pathobiology of increased troponin concentrations in stable patients is currently not established. Moreover, controversy still exists as to whether troponin measurements may prove to be useful tools for detecting reversible myocardial ischemia (12 ) . Theoretically, an early releasable free cytosolic pool of troponin constituting 5%-8% of the total intracellular troponin content may be released from viable cardiomyocytes by several mechanism (12 ) . These potential release mechanisms include transport across a compromised cell membrane (13 ) and the development of cytoplasmic membranous blebs during ischemia (14 ) . Considering that transport across the cell membrane is a prerequisite for the release of troponin from viable cardiomyocytes, the smaller size of cTnI (approximately 26 kDa) (15 ) compared with cTnT (37-39 kDa) (16 ) could make cTnI a superior biomarker to detect reversible ischemia. This hypothesis also has support in the literature because hs-cTnI concentrations have been found to be selectively increased in patients with reversible myocardial ischemia (17 ) , whereas hs-cTnT does not seem to be increased (18 -20 ) . Accordingly, in this study we wanted to test the hypothesis that hs-cTnI concentrations are associated with reversible myocardial ischemia and explore variables that influence troponin concentrations in stable patients.
Methods

STUDY DESIGN
The Akershus Cardiac Examination (ACE) 1 study is a prospective study that includes 200 patients with suspected reversible myocardial ischemia referred to Akershus University Hospital, a teaching hospital in Norway, for myocardial perfusion imaging (MPI) in [2007] [2008] . The study protocol of the ACE 1 study has been reported (19, 21 ) . We included consecutive patients according to a stratified protocol with 50 patients included from the low-risk stratum (Ͻ33% probability of stable CAD), 100 patients from the intermediaterisk stratum (33%-67%), and 50 patients from the high-risk stratum (Ͼ67%). A cardiologist who was blinded to the troponin concentrations determined patient classification based on hospital records and current symptoms. All patients (age Ͼ18 years) who were without left ventricular (LV) bundle branch block with weight Յ120 kg and who were free from disseminated malignant disease and were able to perform a maximal bicycle exercise stress test were eligible for inclusion. Two patients were excluded shortly after stress testing because of diagnoses of disseminated cancer, leaving a final study cohort of 198 patients. We obtained information on comorbidities, history of CAD, previous myocardial infarction (MI), and medication directly from the patients and from hospital records, and we calculated LV hypertrophy in the resting electrocardiogram (ECG) according to the criteria of Sokolow (22 ) . The study was conducted according to the Declaration of Helsinki and was approved by the local ethics committees, and all patients provided informed consent before study commencement.
EXERCISE STRESS TEST AND MPI PROTOCOL
We performed myocardial perfusion imaging (MPI) by a stress-rest imaging protocol with a maximal bicycle test starting at 50 W and increasing by 10 W/min, and we recorded symptoms, heart rate, blood pressure, and a 12-lead ECG before, during, and after the stress test. The exercise stress test was terminated if there was physical exhaustion or severe chest pain, Ͼ2 mm horizontal or downsloping ST-segment depression, Ͼ20 mmHg decrease in systolic blood pressure, or sustained ventricular arrhythmias. We recorded the duration and the workload (W) of the test and calculated metabolic equivalents (METs): [12 ϫ workload (W) ϩ 300]/ [weight (kg) ϫ 3.5]. The exercise ECGs were assessed by a cardiologist without knowledge of troponin concentrations in the patients, and Ͼ0.1 mV horizontal or downsloping ST-segment depression 0.08 s after the J-point and/or characteristic symptoms were considered a positive stress test.
We infused 250 -350 MBq of technetium-99m tetrofosmin intravenously at peak stress to perform MPI and the patient continued exercise for Ն1 min after the injection. Stress images were obtained 45 min after tracer infusion. To obtain rest images, 750 -900 MBq was infused 3-4 h after the exercise test, and images were obtained 45 min after tracer injection. We used a 2-headed ␥ camera (DST-XL, GE Healthcare Technologies) equipped with a low-energy, highresolution collimator for single photon emission computed tomography, and data were reconstructed into short-axis, vertical long-axis, and horizontal long-axis slices. A 17-segment myocardial model was used for visual perfusion rating, with each segment given a score of 0 -4 by a specialist in nuclear medicine with no knowledge of troponin concentrations but with access to the Quantitative Perfusion Spect software. We categorized patients according to evidence of reversible myocardial ischemia and/or previous MI and calculated LV ejection fraction (LVEF) with the Quantitative Gated Spect software.
BLOOD SAMPLING AND TROPONIN MEASUREMENTS
An intravenous line was inserted in an antecubital vein and blood samples were collected into serum tubes before (baseline), immediately after, and 1.5 and 4.5 h after stress testing. Blood samples were put on ice, processed within 1 h of collection, and later stored at Ϫ80°C before analysis. The samples had been through 1 thaw-freeze cycle before cTnI analysis. We measured cTnI by a prototype hs assay (ARCHITECT STAT high-sensitivity troponin, Abbott Diagnostics) with the capture antibody detecting epitopes 24 -40 and the detection antibody epitopes 41-49 of cTnI. The limit of detection (LoD) for the hs-cTnI assay was recently reported by other groups to be 1.2 ng/L, the 99th percentile 16 ng/L, and the assay 10% CV 3.0 ng/L (3 ). CVs in our laboratory were 4.3% for hs-cTnI ϭ 20 ng/L, 3.5% for hs-cTnI ϭ 200 ng/L, and 5.0% for hs-cTnI ϭ 15 000 ng/L (n ϭ 20). cTnT concentrations were measured by a commercially available assay, the Elecsys TNT hs STAT (Roche Diagnostics: reagent lot #156593, calibrator lot #154103, released September 2009) and were not affected by decreased recovery or the introduction of a revised calibration curve (see the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/ vol58/issue11). Thus, cTnT measurements were performed as previously reported (19 ) and with an analytical measurement range of 3-10000 ng/L (23 ) . CVs in our laboratory were Ͻ10% for hs-cTnT ϭ 13 ng/L, 3.4% for hs-cTnT ϭ 25 ng/L, 2.5% for hs-cTnT ϭ 70 ng/L, and 3.0% for hs-cTnT ϭ 1000 ng/L (n Ն 24). Samples with concentrations below the range of the assays were assigned values of 1.2 and 3.0 ng/L for cTnI and cTnT, respectively.
We measured serum creatinine by a standard method, and creatinine clearance was calculated with the Cockcroft-Gault formula (24 ) . All laboratory analyses were performed by personnel blinded to clinical information and MPI results.
STATISTICAL ANALYSIS
Distributional normality of continuous variables was assessed by the Kolmogorov-Smirnov test. Continuous variables are presented as mean (SD) or median [quartile (Q) [1] [2] [3] and categorical variables as absolute numbers and percentages. Differences between patients with and without reversible ischemia at each time point were compared with the Student t-test and the Mann-Whitney U-test for continuous variables and the 2 test for categorical variables. We used the nonparametric related-samples Friedman ANOVA test to assess whether troponin concentrations changed at any time point during the course of blood sampling in the different groups, whereas changes from baseline measurements to (a) measurements immediately after the exercise test, (b) measurements 1.5 h after the test, or (c) measurements 4.5 h after the test were assessed with the Wilcoxon matched-pairs signed-rank test. Variables associated with baseline concentrations of the 2 troponin assays were examined using backward selection from the full multivariate regression models and included age; sex; body mass index; history of heart failure, CAD, diabetes mellitus, and hypertension; baseline diastolic and systolic blood pressure and heart rate; LV hypertrophy; LVEF; creatinine clearance; evidence of reversible myocardial ischemia and/or previous MI (as diagnosed by MPI); and medication [␤ blockers, acetyl salicylic acid, clopidogrel, angiotensinconverting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), and statins]. Because of a skewed distribution, cTnI and cTnT concentrations were transformed by the natural logarithm before regression analysis. To explore variables associated with changes in troponin concentrations during exercise stress testing, METs, maximal diastolic and systolic blood pressure, and maximal heart rate were included in addition to the variables of the baseline models. We used logistic regression analysis to examine variables associated with reversible myocardial ischemia, and the model included all of the covariates of the baseline regression models, the ECG result on exercise stress testing, and hs-cTnI and hscTnT concentrations. The troponin assays were examined both separately and together. Diagnostic accuracy was assessed by ROC analysis, and the areas under the ROC curve (AUCs) were compared (25 ) . We did not adjust for multiple comparisons, and a P value of Ͻ0.05 was considered significant for all analyses. Statistical analyses were performed with PASW for Windows version 19.0 (SPSS, IBM) with the exception of the ROC curve analysis, which was performed with MedCalc for Windows, version 12.1.4.0 (MedCalc Software).
Results
PATIENT CHARACTERISTICS
The baseline characteristics of patients divided according to presence or absence of reversible myocardial ischemia on MPI are presented in Table 1 . Of the 198 patients, 19 patients (10%) were classified as having reversible myocardial ischemia and 20 patients (10%) were found to have evidence of previous MI on the basis of MPI. Six patients had images indicating both reversible ischemia and previous MI. In total, 43 patients (22%) had a history of MI.
In baseline measurements, hs-cTnI concentrations were below the measurement range in 35 patients (18%) compared to 53 patients (27%) for the hs-cTnT assay. In total, 126 patients (64%) had simultaneously detectable baseline concentrations of hs-cTnI and hscTnT. Using LoD (e.g., the 95th percentile concentration from n Ն 60 measurements of analyte-free sample ϭ 5 ng/L) (23 ) as the lower limit for the hs-cTnT assay, 83 patients (42%) had hs-cTnT concentrations below the range of the assay. In multivariate analysis, older age (P Ͻ 0.001) and male sex (P Ͻ 0.001) increased the odds ratio of having detectable hs-cTnI concentrations, whereas statin use (P ϭ 0.01) decreased the odds ratio. For hs-cTnT concentrations, a reduction in creatinine clearance increased the odds ratio of having detectable concentrations (P ϭ 0.01), as did analysis with the LoD as the lower range of the assay (P Ͻ 0.001).
Baseline hs-cTnI concentrations were higher in patients with reversible myocardial ischemia compared to the patients without reversible ischemia: median 4.4 (Q 1-3: 2.3-7.1) vs 2.5 (1.4 -4.3), P ϭ 0.003. The correlation 
TROPONIN I MEASUREMENTS AFTER EXERCISE STRESS TESTING
As examined with the Friedman test, hs-cTnI concentrations were significantly influenced by exercise stress testing in patients with (P ϭ 0.001) and without reversible ischemia (P Ͻ 0.001) (Fig. 1) . For the hs-cTnT assay, only patients without reversible myocardial ischemia demonstrated significant increments in concentrations after exercise stress testing (P Ͻ 0.001). In patients with reversible myocardial ischemia, there was no increase in hs-cTnI concentrations until 4.5 h after the exercise stress test: 6.9 (3.9 -9.3) ng/L, P ϭ 0.01 vs baseline concentrations. In contrast, hs-cTnI concentrations increased immediately after the stress test in patients without reversible ischemia [2.7 (1.5-4.3) ng/L, P Ͻ 0.001 vs baseline]. Baseline hs-cTnI concentrations were closely correlated with the concentrations measured after exercise stress testing: r ϭ 0.94 (immediately after), r ϭ 0.87 (1.5 h after), and r ϭ 0.69 (4.5 h after) (P Ͻ 0.001 for all). In multivariate analysis, no variables in our models were significantly associated with change in either hs-cTnI or hs-cTnT concentrations. Moreover, there were no significant correlations of changes in hs-cTnI and hs-cTnT concentrations between any time points.
ASSOCIATION BETWEEN TROPONIN I MEASUREMENTS AND REVERSIBLE MYOCARDIAL ISCHEMIA
We found hs-cTnI concentrations to be higher at all time points except 4.5 h after the stress test in patients with reversible myocardial ischemia compared with the other patients ( Table 2 ). In contrast, changes (⌬ values) in hs-cTnI concentrations from baseline to later time points were comparable in patients with and without reversible myocardial ischemia ( Table 2 ). The ability of the hs-cTnI assay to identify patients with reversible myocardial ischemia, as assessed by ROC analysis, did not improve when we measured hs-cTnI after exercise stress testing nor when we calculated the change in hs-cTnI concentrations from baseline to later time points ( Table 2 ). The accuracy of hs-cTnI concentrations to identify patients with reversible myocardial ischemia was comparable to that of hscTnT concentrations at all time points. In patients without reversible myocardial ischemia, those with a history of MI (n ϭ 33) had significantly higher hs-cTnI concentrations compared with patients with no previous MI (n ϭ 146) at all time points (Fig. 2) . Patients with no reversible ischemia but previous MI had hs-cTnI and hs-cTnT concentrations comparable to and release profiles during stress testing similar to those of patients with reversible myocardial ischemia with concentrations increased only 4.5 h after exercise stress testing (P Ͻ 0.001 for both vs baseline concentrations). In contrast, hs-cTnI concentrations increased immediately after the stress test (P Ͻ 0.001) and hs-cTnT concentrations 1.5 h after the stress test (P ϭ 0.007) in patients with no reversible ischemia and Fig. 1 . hs-cTnI and hs-cTnT concentrations before and after exercise stress testing in patients with (n ‫؍‬ 19) and without (n ‫؍‬ 179) reversible myocardial ischemia.
The horizontal line within the box represents the median concentration, the boundaries of the box quartiles 1-3, and the whiskers range (maximum value restricted to 1.5 times the interquartile range from the median). The numbers of patients with concentrations in the detectable range of the assay are reported in the parentheses.
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no history of MI. For the patients with reversible ischemia, patients with (n ϭ 10) and without previous MI (n ϭ 9) had comparable hs-cTnI and hs-cTnT concentrations at all time points and similar release profiles, i.e., hs-cTnI concentrations were increased only after 4.5 h, whereas no increment in hs-cTnT concentrations was observed (see the online Supplemental Figure) .
BASELINE TROPONIN MEASUREMENTS AND REVERSIBLE
MYOCARDIAL ISCHEMIA IN REGRESSION MODELS
Because hs-cTnI and hs-cTnT concentrations measured up to 4.5 h after exercise stress testing did not add to information obtained from baseline values, further analyses were confined to baseline measurements. By univariate logistic regression analysis, increasing hscTnI concentrations (logarithmically transformed) were associated with reversible myocardial ischemia: odds ratio 1.55 (95% CI 1.07-2.26), P ϭ 0.02. Other variables associated with reversible ischemia in univariate analysis were male sex, history of CAD, a positive exercise stress test, cardiac medications, and increasing hs-cTnT concentrations. In multivariate analysis, the associations for hs-cTnI and hs-cTnT with reversible myocardial ischemia were attenuated and no longer significant.
In a multivariate linear regression model that explained 51% of the variance, baseline hs-cTnI concentrations were positively influenced by age (P Ͻ 0.001), male sex (P ϭ 0.009), history of hypertension (P ϭ 0.002), use of ACEI (P ϭ 0.024), and a reduction in LVEF (P ϭ 0.004), whereas male sex (P ϭ 0.032), history of diabetes mellitus (P ϭ 0.009), baseline systolic blood pressure (P ϭ 0.048), and a reduction in creatinine clearance (P ϭ 0.002) were all positively associated with higher baseline hs-cTnT concentrations (r 2 ϭ 0.40) ( Table 3) .
Discussion
The principal findings of our study were (a) the prototype hs-cTnI assay can measure troponin in a larger proportion of patients with suspected stable CAD than the hs-cTnT assay; (b) neither hs-cTnI nor hs-cTnT measurements identify patients with reversible myocardial ischemia in a clinically useful manner; and (c) circulating troponin concentrations seem to be influenced by variables associated with structural alterations of the myocardium. Several models for troponin release have been proposed and it is plausible that troponin may also be released in situations other than cardiomyocyte necrosis (12) (13) (14) . First, the nonnecrotic release of troponins is considered to represent release from the free cytosolic pool of troponins. The smaller size of cTnI compared to cTnT led us to hypothesize that hs-cTnI could be a superior biomarker to hs-cTnT for detection of revers- Table 2 . Troponin I and T concentrations before and after exercise stress testing in patients with (n ‫؍‬ 19) and without (n ‫؍‬ 179) reversible myocardial ischemia on MPI.
Reversible ischemia (n ‫؍‬ 19)
No reversible ischemia (n ‫؍‬ ible myocardial ischemia. This hypothesis also has some support in the literature. In a previous publication from the ACE 1 study, we found no association between reversible myocardial ischemia and the release of hs-cTnT during exercise stress testing (19 ) . Although the modest number of patients with reversible ischemia in our study may increase the likelihood of a type II error, the lack of increment in hs-cTnT concentrations after exercise stress testing is in accordance with earlier results by Kurz et al. (18 ) . In contrast, with the use of a different highly sensitive assay for cTnI, the Thrombolysis In Myocardial Infarction (TIMI) study group found increased hs-cTnI concentrations after stress testing in patients with reversible ischemia, whereas concentrations in patients without ischemia were not significantly increased (17 ) . In the present work, after exercise stress testing in patients with reversible myocardial ischemia we found increases in hs-cTnI concentrations of comparable magnitude to those reported by the TIMI group (median 50% increment after 4.5 h compared to a 20%-40% increment after 4 h in the TIMI study). However, in direct contrast to their results, we found that hs-cTnI concentrations increase after exercise stress testing in patients without reversible myocardial ischemia, thus resulting in a substantial overlap in troponin values between patients with and without reversible myocardial ischemia. Accordingly, neither hs-cTnI nor hscTnT measurements provided incremental information over that from clinical variables in multivariate models. We do not have a clear explanation for this discrepancy, but our results are in line with the dynamic increment of cTnI reported in healthy individuals during strenuous physical activity like marathon running (26, 27 ) , and the results for hs-cTnT in the ACE 1 study (19 ) . Extrapolation from marathon runners with cTnI release and no evidence of subtle myocardial necrosis by cardiac magnetic resonance imag- Fig. 2 . hs-cTnI and hs-cTnT concentrations before and after exercise stress testing in patients without reversible ischemia and no previous MI (n ‫؍‬ 146), in patients without reversible ischemia but previous MI (n ‫؍‬ 33), and in patients with reversible myocardial ischemia (n ‫؍‬ 19).
The horizontal line within the box represents the median concentration, the boundaries of the box represent Q 1-3, and the whiskers represent the range (maximum value restricted to 1.5 times the interquartile range from the median). The numbers of patients in each patient group with concentrations in the detectable range of the assay are reported in parentheses. 
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ing (26, 27 ) suggests that mechanisms other than cardiomyocyte necrosis should be considered responsible for the cTnI release in patients with MPI results within reference intervals. Although some studies have demonstrated associations with exercise duration, fitness levels of the participants, cardiovascular pathology, and evidence of reversible right ventricular dysfunction after exercise, no clear consensus exists to explain the heterogeneity of troponin release after physical activity (28 ) . In line with previous findings, no variable in our comprehensive multivariate models that also included METs was associated with changes in hs-cTnI or hs-cTnT concentrations during stress testing. Furthermore, our data suggest that the release kinetics of cTnI and cTnT may differ, because the change in hs-cTnI concentrations did not correlate with the change in hs-cTnT concentrations.
One surprise finding of our study was the apparent blunted troponin release after stress testing in the patients with either previous or current myocardial ischemia. Our data require validation in larger cohorts and should be interpreted cautiously given the modest number of patients with reversible myocardial ischemia. However, there is some support for this result in the literature. A recent atrial pacing and coronary sinus sampling study revealed a blunted response in hs-cTnT concentrations over the myocardium in patients with coronary artery stenosis and myocardial lactate production (indicating ischemia), whereas individuals without CAD and with no lactate production demonstrated a substantial increase in hs-cTnT concentrations in the coronary sinus following Ͻ60 min of pacing (20 ) . Although speculative, a putative mechanism for the attenuated response could be continuous steady-state release of troponin to the circulation in patients with chronic CAD, which would render fewer troponin molecules available for swift release from the free cytosolic pool in situations of myocardial strain. In support of this hypothesis, there is increasing recognition that patients with chronic CAD have higher baseline hs-cTnT concentrations than individuals from the general population (29 ) . However, to establish whether our proposed model of cytosolic troponin release in patients with CAD is valid will require additional clinical and experimental studies.
In our study, the measurement of troponin concentrations up to 4.5 h after exercise stress testing or the calculation of the change in troponin concentrations during exercise stress testing did not improve diagnostic accuracy for detection of ischemia compared to baseline measurements. However, we cannot exclude that measurements performed after 4.5 h might have provided additional information. The correlation coefficient between hs-cTnI and hs-cTnT concentrations was of only moderate strength, which may indicate that there could be subtle differences between cTnI and cTnT measurements. Moreover, we found that both troponin assays were influenced by variables that over time induce structural alterations in the myocardium. However, given the difference in the number of patients with hs-cTnI and hs-cTnT concentrations in the detectable range, whether the differences in the variables influencing hs-cTnT and hs-cTnI concentrations observed in our study are valid requires validation in larger data sets.
A limitation of our study was the moderate number of patients with reversible myocardial ischemia; hence the cTnI and cTnT concentration profiles in patients with reversible ischemia are based on a limited number of study participants. However, in the ACE 1 study we recently demonstrated a dynamic rise and fall in B-type natriuretic peptide concentrations in relation to the exercise stress test. This result is analogous to data reported by other groups (21 ) , which supports the validity of the current findings.
In conclusion, we have demonstrated that although the prototype hs-cTnI assay measures troponin in a larger proportion of stable patients than the hscTnT assay, neither troponin assay provides clinically relevant information to identify reversible myocardial ischemia. Hence, there is a need for additional clinical and experimental studies to understand the mechanism for troponin release during exercise stress testing.
